Mirati Therapeutics, Inc. is a San Diego-based biotechnology company that focuses on developing targeted therapies to improve the lives of patients. Their mission is to convert possibility into reality by advancing research and development programs targeting specific mutations, such as KRASG12C and KRASG12D, in order to tackle cancer head-on. With a pipeline of novel therapeutics, Mirati is committed to making a significant impact in the field of oncology.
Through their rigorous scientific approach, Mirati aims to address the unmet needs of patients with advanced non-small cell lung cancer (NSCLC) and other cancers. Their investigational drugs, including KRAZATI adagrasib and MRTX1719, have shown promising results in clinical trials and have received approvals from regulatory authorities. Mirati Therapeutics is dedicated to making a difference in the fight against cancer and is driven by a strong commitment to patients and their well-being.
Generated from the website